UPDATE 1-AstraZeneca in $815 mln 'high altitude' anaemia pill deal

03:06 EDT 31 Jul 2013 | Reuters

LONDON, July 31 (Reuters) - AstraZeneca took another step to bolster its new drug pipeline on Wednesday by striking a deal with U.S. biotech firm FibroGen potentially worth more than $815 million for rights to an experimental anaemia drug.

Original Article: UPDATE 1-AstraZeneca in $815 mln 'high altitude' anaemia pill deal

NEXT ARTICLE

More From BioPortfolio on "UPDATE 1-AstraZeneca in $815 mln 'high altitude' anaemia pill deal"

Search BioPortfolio:
Advertisement

Relevant Topics

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Biotechnology - Biotech
Latest News Clinical Trials Research Drugs Reports Corporate
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Advertisement

Searches Linking to this Story